fig3

Adaptive drug resistance in melanoma is characterised by lipidome remodelling while maintaining cell membrane biophysical properties

Figure 3. Schematic overview of treatments applied to melanoma cells prior to lipid extraction and mass spectrometry analysis to obtain outer leaflet lipid composition. Treatment 1: Phospholipids from intact/undigested cells were extracted and analysed to determine the total cellular lipidome. Treatment 2: Cells were incubated with PLA2 for ≤ 30 min at 37 °C to selectively digest phospholipids from the outer leaflet of the plasma membrane, while preserving the integrity of the inner leaflet, which was verified using a LDH assay (not illustrated). Extracts contain a mixture of GPLs from the plasma membrane inner leaflet and from cell organelles; lysophospholipids and free FAs from digested GPLs of the outer leaflet, and Chol and SM. Treatment 3: cells were subjected to freeze–thaw cycles, sonicated and fully digested with PLA2 to confirm enzymatic activity and ability to digest all the GPL classes. Treatment 3 contains lysophospholipids, FA and Chol and SM. The lipid composition of the outer leaflet (O) was obtained by subtracting the lipid profile of Treatment 2 from that of Treatment 1. This is an original figure created using Adobe Illustrator (Version 30.8). PLA2: Phospholipase A2; LDH: lactate dehydrogenase; GPLs: glycerophospholipids; FAs: fatty acids; Chol: cholesterol; SM: sphingomyelin.

Cancer Drug Resistance
ISSN 2578-532X (Online)

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/